The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB ... KB104 for treating netherton syndrome; KB407 that is in Phase ...

Two years previously, TKT signed an exclusive licensing agreement with Genzyme Corporation to market Elaprase (idursulfase), which is a drug used to treat Hunter syndrome (also called MPS-II), in ...

Jeremiah Marshall, a 33-year-old man from San Diego, California, suffers from one of the world's rarest conditions, epidermolysis bullosa, which makes his skin so delicate that even a slight touch ...

Epidermolysis bullosa (EB) is the term given to a group of inherited mechanobullous disorders involving blistering of the skin and sometimes mucous membranes in response to minor frictional trauma.

Jeremiah Marshall, 33, has epidermolysis bullosa, a rare genetic disorder that makes his skin tear or blister at the ...

might be more valuable than a company that is developing drugs for Ogilvie's Syndrome, a rare disease that only affects 1%–3% of the population. Every new drug developed by biotech firms has to ...

After hours: January 28 at 4:09:06 PM EST Loading Chart for KRYS ...